Virotherapy News and Research

RSS

Virotherapy is treatment using a virus that has been changed in the laboratory to find and destroy cancer cells without harming healthy cells. It is a type of targeted therapy. Also called oncolytic virotherapy, oncolytic virus therapy, and viral therapy.

Zika virus live-attenuated vaccine strains show promise in brain cancer treatment

Scientists from Duke-NUS Medical School (Duke-NUS) have developed a new approach using the Zika virus to destroy brain cancer cells and inhibit tumor growth, while sparing healthy cells.

8 Mar 2024

Breaking barriers: hydrogel reservoir unleashes the potential of HSV-1 virotherapy in cancer

Researchers evaluated the therapeutic efficacy of Navoximod.

13 Jun 2023

Researchers identify a potential breakthrough in glioblastoma treatment

In a recently published manuscript, Howard Colman, MD, PhD, Jon M. Huntsman Presidential Professor of Neuro-Oncology and co-leader of the Neurologic Cancers Disease Center and the Experimental Therapeutics CCSG program at Huntsman Cancer Institute, identified a potential breakthrough in glioblastoma treatment.

12 Jun 2023

Clinical trial of a combination treatment shows great promise for patients with glioblastoma

A new international study published in Nature Medicine and presented as a late-breaking abstract at the American Association of Neurological Surgeons annual conference, shows great promise for patients with glioblastoma.

15 May 2023

MD Anderson and Virogin Biotech partner to accelerate the development of investigational treatments for advanced cancers

The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.

7 Sep 2022

Oncolytic viruses boost the immune capacity to effectively target and destroy cancer cells

The immune system has evolved to safeguard the body from a wildly diverse range of potential threats. Among these are bacterial diseases, including plague, cholera, diphtheria and Lyme disease, and viral contagions such as influenza, Ebola virus and SARS CoV-2.

29 Aug 2022

Genetically modified herpes virus can be used in the fight against cancer

Viruses can make animals and humans sick - or healthy: Researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB have succeeded in genetically modifying the herpes simplex virus type 1, which triggers painful cold sores, in such a way that it can be used in the fight against cancer in the future.

1 Jun 2022

First patient dosed in Phase 1 clinical trial evaluating the safety of CF33-hNIS against solid tumors

Imugene Limited, a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors.

18 May 2022

Study opens up prospects for using virotherapy to treat central nervous system tumors

In a study conducted at the University of São Paulo's Human Genome and Stem Cell Research Center (HUG-CELL) in Brazil, serial systemic injections of zika virus into mice with brain tumors destroyed the cancer without causing neurological damage or injuring other organs, and increased the animals' survival rate.

11 Jan 2022

Peto's paradox offers new insights into cancer risk across mammals

The cells in the body can be thought of as tiny archery targets, each vulnerable to the deadly arrow of cancer.

23 Dec 2021

Review highlights oncolytic viruses with remarkable ability to destroy cancer cells

With the world still in the grip of a devastating pandemic, it's hard to imagine viruses as something other than hostile enemies to be vanquished.

30 Nov 2021

Personalized vaccine can provide effective immunization against cancer

Marie-Claude Bourgeois-Daigneault and her team at the CRCHUM are using mice to show how a combination of peptides and oncolytic viruses, used as an adjuvant, can provide effective immunization against cancer.

11 May 2021

Novel platform uses modified virus to combat pancreatic cancer

Researchers from Queen Mary University of London and Zhengzhou University have developed a powerful therapeutic platform that uses a modified virus for the treatment of pancreatic cancer.

26 Jan 2021

Scientists solve 3D structure of vaccinia virus RNA polymerase

For viruses to multiply, they usually need the support of the cells they infect. In many cases, only in their host's nucleus can they find the machines, enzymes and building blocks with which they can multiply their genetic material before infecting other cells.

12 Dec 2019

Children's of Alabama using cold sore virus to fight pediatric brain cancer

Children's of Alabama is home to one of the most exciting studies underway in pediatric cancer: evaluating the use of a cold sore virus to treat children with progressive malignant brain tumors.

26 Sep 2019

PCRF awards £1.2M grants for new research projects tackling pancreatic cancer

Seven innovative research projects tackling pancreatic cancer have been awarded grants totalling £1.2M by the UK medical research charity, Pancreatic Cancer Research Fund.

28 May 2019

Study reveals how Seneca Valley Virus interacts with tumor receptors

Seneca Valley Virus sounds like the last bug you’d want to catch, but it could be the next breakthrough cancer therapy.

30 Oct 2018

Themis, Max-Planck-Innovation sign license agreement to develop and commercialize oncolytic virotherapies

Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. Financial terms of the agreement were not disclosed.

11 Oct 2018

Researchers develop cancer vaccine platform to improve efficacy of oncolytic enveloped viruses

Researchers at the Faculty of Pharmacy have developed PeptiENV, a cancer vaccine platform, which can be used to improve the therapeutic efficacy of oncolytic enveloped viruses currently in clinical use.

6 Oct 2018

New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers

Ludwig Cancer Research and the Cancer Research Institute announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI (durvalumab) for advanced ovarian and colorectal cancers.

12 Jul 2018